Your session is about to expire
← Back to Search
Chemoimmunotherapy for Prostate Cancer (CHAMP Trial)
CHAMP Trial Summary
This trial is testing the safety and efficacy of a combination of four drugs to treat men with aggressive prostate cancer. The four drugs are nivolumab, ipilimumab, cabazitaxel, and carboplatin. The trial will also investigate biomarkers to understand how the drug combination affects prostate cancer and the immune system.
CHAMP Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCHAMP Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.CHAMP Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not received a live vaccine in the last 30 days.I am currently being treated for an infection.I am older than 18 years.I have had cabazitaxel or at least two chemotherapy treatments for prostate cancer.I have been treated for prostate cancer with specific hormone therapies within the last two weeks.I agree to use effective birth control and not donate sperm while on cabazitaxel treatment.I have an active tuberculosis infection.I have moderate to severe nerve damage.I have received an organ or tissue transplant from another person.I haven't had any cancer treatment or experimental drugs in the last 4 weeks.I have HIV with a viral load that isn't under control and a low CD4 count.My cancer tissue samples are available for study.I am mostly able to care for myself and carry out normal activities.My prostate cancer is neuroendocrine-like, confirmed by tests or symptoms.I had another type of cancer but have been cancer-free for 2 years after treatment.I haven't needed systemic treatment for an autoimmune disease in the last 2 years.My testosterone levels are very low or I am on hormone therapy.I have stable brain metastases and haven't needed high doses of steroids recently.I had radiotherapy over 2 weeks ago, recovered from side effects, and didn't have lung inflammation from it.You currently have active Hepatitis B or Hepatitis C infection.I have an immune system disorder or have been on high-dose steroids or other drugs that weaken my immune system recently.I have had or currently have lung inflammation treated with steroids.My prostate cancer is spreading despite treatment.I have been treated with specific immune therapy drugs before.
- Group 1: Neuroendocrine Prostate Cancer (NEPC) or Aggressive Variant Prostate Cancer (AVPC)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What precautionary measures should be taken when using Nivolumab?
"The safety of Nivolumab was evaluated by Power and given a score of 2 due to the fact that it is in Phase 2 trials, meaning there has been some research regarding its security but nothing yet verifying its efficacy."
What are the primary applications of Nivolumab?
"Nivolumab is primarily used to combat malignant neoplasms, but can also help patients with dangerous and recurrent cases of unresectable melanoma and squamous cell carcinoma."
How often has Nivolumab been utilized in clinical research?
"Currently, there are 1,430 clinical trials assessing the effects of Nivolumab with 298 in their final stage. While some tests occur specifically within Shanghai, an array of 83,733 sites are investigating this drug."
How many applicants are being admitted to this medical trial?
"Verified. The clinical trial is currently enrolling patients and the information present on clinicialtrials.gov attests to this; it was initially added on June 7th 2021, and edited most recently on June 2nd 2022. There are 43 positions available across 1 site for prospective participants."
Are there any vacancies for individuals to partake in this clinical trial?
"Per the details on clinicaltrials.gov, enrolment for this medical trial is currently happening. It was released to the public on June 7th 2021 and updated as recently as June 2nd 2022."
Share this study with friends
Copy Link
Messenger